174 related articles for article (PubMed ID: 38582286)
1. Evaluation of Circulating Endothelial Cells as Direct Marker of Endothelial Damage in Allo-Transplant Recipients at High Risk of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome.
Farina M; Scaini MC; Facchinetti A; Leoni A; Bernardi S; Catoni C; Morello E; Radici V; Frioni F; Campodonico E; Traverso G; Cavallaro G; Olivieri A; Galieni P; Renzo ND; Patriarca F; Carluccio P; Skert C; Maffini E; Pellizzeri S; Campisi G; Re F; Benedetti E; Rosato A; Almici C; Chiusolo P; Peccatori J; Malagola M; Poggiana C; Russo D
Transplant Cell Ther; 2024 Jun; 30(6):580.e1-580.e14. PubMed ID: 38582286
[TBL] [Abstract][Full Text] [Related]
2. Earlier defibrotide initiation post-diagnosis of veno-occlusive disease/sinusoidal obstruction syndrome improves Day +100 survival following haematopoietic stem cell transplantation.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ
Br J Haematol; 2017 Jul; 178(1):112-118. PubMed ID: 28444784
[TBL] [Abstract][Full Text] [Related]
3. BCSH/BSBMT guideline: diagnosis and management of veno-occlusive disease (sinusoidal obstruction syndrome) following haematopoietic stem cell transplantation.
Dignan FL; Wynn RF; Hadzic N; Karani J; Quaglia A; Pagliuca A; Veys P; Potter MN; ;
Br J Haematol; 2013 Nov; 163(4):444-57. PubMed ID: 24102514
[TBL] [Abstract][Full Text] [Related]
4. Defibrotide for Patients with Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome: Interim Results from a Treatment IND Study.
Richardson PG; Smith AR; Triplett BM; Kernan NA; Grupp SA; Antin JH; Lehmann L; Shore T; Iacobelli M; Miloslavsky M; Hume R; Hannah AL; Nejadnik B; Soiffer RJ;
Biol Blood Marrow Transplant; 2017 Jun; 23(6):997-1004. PubMed ID: 28285079
[TBL] [Abstract][Full Text] [Related]
5. [Diagnosis and treatment of sinusoidal obstruction syndrome (veno-occlusive disease)].
Kikuta A
Rinsho Ketsueki; 2021; 62(8):1256-1264. PubMed ID: 34497214
[TBL] [Abstract][Full Text] [Related]
6. Prognostic Biomarkers for Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome in Myeloablative Allogeneic Hematopoietic Cell Transplantation: Results from the Blood and Marrow Transplant Clinical Trials Network 1202 Study.
Putta S; Young BA; Levine JE; Reshef R; Nakamura R; Strouse C; Perales MA; Howard A; Pine P; Shi J; Zhang P; Ho VT; Saber W
Transplant Cell Ther; 2023 Mar; 29(3):166.e1-166.e10. PubMed ID: 36574581
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of defibrotide in the prevention of hepatic venooclusive disease among adult patients receiving allogeneic hematopoietic cell transplantation: A retrospective single center experience.
Kayikci O; Akpinar S; Tekgunduz E
Transfus Apher Sci; 2022 Feb; 61(1):103369. PubMed ID: 35120824
[TBL] [Abstract][Full Text] [Related]
8. Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation.
Roeker LE; Kim HT; Glotzbecker B; Nageshwar P; Nikiforow S; Koreth J; Armand P; Cutler C; Alyea EP; Antin JH; Richardson PG; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2019 Jan; 25(1):137-144. PubMed ID: 30081073
[TBL] [Abstract][Full Text] [Related]
9. Incidence of Anicteric Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome and Outcomes with Defibrotide following Hematopoietic Cell Transplantation in Adult and Pediatric Patients.
Corbacioglu S; Kernan NA; Pagliuca A; Ryan RJ; Tappe W; Richardson PG
Biol Blood Marrow Transplant; 2020 Jul; 26(7):1342-1349. PubMed ID: 32200121
[TBL] [Abstract][Full Text] [Related]
10. Autotaxin is a potential predictive marker for the development of veno-occlusive disease/sinusoidal obstruction syndrome after allogeneic hematopoietic cell transplantation.
Takemura K; Nakamae M; Okamura H; Sakatoku K; Ido K; Makuuchi Y; Kuno M; Takakuwa T; Hirose A; Nishimoto M; Nakashima Y; Koh H; Igarashi K; Kubota H; Hino M; Nakamae H
Ann Hematol; 2024 May; 103(5):1705-1715. PubMed ID: 38494552
[TBL] [Abstract][Full Text] [Related]
11. Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation.
Lewis C; Kim HT; Roeker LE; Cutler C; Koreth J; Nikiforow S; Armand P; Gootpu M; Romee R; Glotzbecker B; Nageshwar P; Antin JH; Alyea EP; Richardson P; Soiffer RJ; Ho VT
Biol Blood Marrow Transplant; 2020 Mar; 26(3):529-539. PubMed ID: 31678537
[TBL] [Abstract][Full Text] [Related]
12. Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease after Autologous or Allogeneic Hematopoietic Stem Cell Transplantation in Children: a retrospective study of the Italian Hematology-Oncology Association-Hematopoietic Stem Cell Transplantation Group.
Faraci M; Bertaina A; Luksch R; Calore E; Lanino E; Saglio F; Prete A; Menconi M; De Simone G; Tintori V; Cesaro S; Santarone S; Orofino MG; Locatelli F; Zecca M
Biol Blood Marrow Transplant; 2019 Feb; 25(2):313-320. PubMed ID: 30266674
[TBL] [Abstract][Full Text] [Related]
13. Defibrotide for Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease Prophylaxis in High-Risk Adult Patients: A Single-Center Experience Study.
Picod A; Bonnin A; Battipaglia G; Giannotti F; Ruggeri A; Brissot E; Malard F; Médiavilla C; Belhocine R; Vekhoff A; Gueye MS; Lapusan S; Adaeva R; Isnard F; Legrand O; Baylatry MT; Joly AC; Labopin M; Duléry R; Mohty M
Biol Blood Marrow Transplant; 2018 Jul; 24(7):1471-1475. PubMed ID: 29477779
[TBL] [Abstract][Full Text] [Related]
14. Incidence of Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease and Treatment with Defibrotide in Allogeneic Transplantation: A Multicenter Australasian Registry Study.
Coutsouvelis J; Kirkpatrick CM; Dooley M; Spencer A; Kennedy G; Chau M; Huang G; Doocey R; Copeland TS; Do L; Bardy P; Kerridge I; Cole T; Fraser C; Perera T; Larsen SR; Mason K; O'Brien TA; Shaw PJ; Teague L; Butler A; Watson AM; Ramachandran S; Marsh J; Khan Z; Hamad N
Transplant Cell Ther; 2023 Jun; 29(6):383.e1-383.e10. PubMed ID: 36934993
[TBL] [Abstract][Full Text] [Related]
15. Defibrotide for children and adults with hepatic veno-occlusive disease post hematopoietic cell transplantation.
Corbacioglu S; Richardson PG
Expert Rev Gastroenterol Hepatol; 2017 Oct; 11(10):885-898. PubMed ID: 28825848
[TBL] [Abstract][Full Text] [Related]
16. Defibrotide sodium for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome.
Richardson PG; Triplett BM; Ho VT; Chao N; Dignan FL; Maglio M; Mohty M
Expert Rev Clin Pharmacol; 2018 Feb; 11(2):113-124. PubMed ID: 29301447
[TBL] [Abstract][Full Text] [Related]
17. Defibrotide: real-world management of veno-occlusive disease/sinusoidal obstructive syndrome after stem cell transplant.
Nauffal M; Kim HT; Richardson PG; Soiffer RJ; Antin JH; Cutler C; Nikiforow S; Gooptu M; Koreth J; Romee R; Ho VT
Blood Adv; 2022 Jan; 6(1):181-188. PubMed ID: 34666352
[TBL] [Abstract][Full Text] [Related]
18. Transjugular Intrahepatic Portosystemic Shunt for Very Severe Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome (VOD/SOS) after Unmanipulated Haploidentical Hematopoietic Stem Cell Transplantation with Post-transplantation Cyclophosphamide.
Gómez-Centurión I; Bailén R; Oarbeascoa G; Muñoz C; Luque AÁ; Boyra ME; Calleja E; Rincón D; Dorado N; Barzallo P; Anguita J; Díez-Martín JL; Kwon M
Biol Blood Marrow Transplant; 2020 Nov; 26(11):2089-2097. PubMed ID: 32791193
[TBL] [Abstract][Full Text] [Related]
19. Hepatic sinusoidal obstruction syndrome/veno-occlusive disease after hematopoietic cell transplantation: historical and current considerations in Korea.
Yoon JH; Choi CW; Won JH
Korean J Intern Med; 2021 Nov; 36(6):1261-1280. PubMed ID: 34555279
[TBL] [Abstract][Full Text] [Related]
20. Defibrotide for the treatment of hepatic veno-occlusive disease/sinusoidal obstruction syndrome following nontransplant-associated chemotherapy: Final results from a post hoc analysis of data from an expanded-access program.
Kernan NA; Richardson PG; Smith AR; Triplett BM; Antin JH; Lehmann L; Messinger Y; Liang W; Hume R; Tappe W; Soiffer RJ; Grupp SA
Pediatr Blood Cancer; 2018 Oct; 65(10):e27269. PubMed ID: 29873895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
